Anika Therapeutics (ANIK) 10-Q 5 Nov 20 2020 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Oct. 26, 2020
Document Information [Line Items]
Entity Central Index Key	0000898437
Entity Registrant Name	Anika Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	000-21326
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3145961
Entity Address, Address Line One	32 Wiggins Avenue
Entity Address, City or Town	Bedford
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01730
City Area Code	781
Local Phone Number	457-9000
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	ANIK
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		14,214,516

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 104,216	$ 157,463
Investments	20,542	27,480
Accounts receivable, net of reserves of $1,055 and $962 at September 30, 2020 and December 31, 2019, respectively	23,009	23,079
Inventories, net	47,882	21,995
Prepaid expenses and other current assets	6,226	4,289
Total current assets	201,875	234,306
Property and equipment, net	51,629	50,783
Right-of-use assets	22,898	22,864
Other long-term assets	13,226	7,478
Intangible assets, net	94,291	7,585
Goodwill	32,419	7,694
Total assets	416,338	330,710
Current liabilities:
Accounts payable	6,800	3,832
Accrued expenses and other current liabilities	24,339	12,445
Total current liabilities	31,139	16,277
Other long-term liabilities	987	357
Contingent consideration	41,045	0
Long-term debt	25,000	0
Deferred tax liability	12,584	4,331
Lease liabilities	21,132	21,367
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.01 par value; 90,000 shares authorized, 14,208 and 14,308 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	142	143
Additional paid-in-capital	52,505	48,707
Accumulated other comprehensive loss	(5,296)	(5,898)
Retained earnings	237,100	245,426
Total stockholders’ equity	284,451	288,378
Total liabilities and stockholders’ equity	$ 416,338	$ 330,710

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable, reserves	$ 1,055	$ 962
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000	90,000
Common stock, shares issued (in shares)	14,208	14,308
Common stock, shares outstanding (in shares)	14,208	14,308

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 31,694	$ 29,697	$ 97,769	$ 84,838
Operating expenses:
Cost of product revenue	14,351	5,951	45,487	20,098
Research & development	5,217	4,158	15,799	12,581
Selling, general & administrative	15,903	7,539	44,884	22,713
Goodwill impairment	0	0	18,144	0
Change in fair value of contingent consideration	4,150	0	(16,176)	0
Total operating expenses	39,621	17,648	108,138	55,392
Income (loss) from operations	(7,927)	12,049	(10,369)	29,446
Interest and other income (expense), net	(228)	482	(118)	1,513
Income (loss) before income taxes	(8,155)	12,531	(10,487)	30,959
Provision for (benefit from) income taxes	(1,744)	3,331	(2,161)	7,817
Net income (loss)	$ (6,411)	$ 9,200	$ (8,326)	$ 23,142
Basic net income (loss) per share:
Net income (loss) (in dollars per share)	$ (0.45)	$ 0.65	$ (0.59)	$ 1.65
Basic weighted average common shares outstanding (in shares)	14,205	14,070	14,202	14,065
Diluted net income (loss) per share:
Net income (loss) (in dollars per share)	$ (0.45)	$ 0.64	$ (0.59)	$ 1.62
Diluted weighted average common shares outstanding (in shares)	14,205	14,387	14,202	14,266
Net income (loss)	$ (6,411)	$ 9,200	$ (8,326)	$ 23,142
Foreign currency translation adjustment	522	(622)	602	(792)
Comprehensive income (loss)	(5,889)	8,578	(7,724)	22,350
Product [Member]
Revenue	31,694	29,615	97,769	84,745
Service [Member]
Revenue	$ 0	$ 82	$ 0	$ 93

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Restricted Stock Units (RSUs) [Member]Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2018		14,210
Balance at Dec. 31, 2018		$ 142	$ 50,763	$ 218,233	$ (5,526)	$ 263,612
Stock-based compensation expense		$ 0	1,386	0	0	1,386
Retirement of common stock for minimum tax withholdings (in shares)		(3)
Retirement of common stock for minimum tax withholdings		$ 0	(124)	0	0	(124)
Net income (loss)		0	0	4,507	0	4,507
Other comprehensive loss		$ 0	0	0	(315)	(315)
Issuance of common stock for equity awards (in shares)		7
Issuance of common stock for equity awards		$ 0	5	0	0	5
Stock-based compensation expense		$ 0	1,386	0	0	1,386
Balance (in shares) at Mar. 31, 2019		14,214
Balance at Mar. 31, 2019		$ 142	52,030	222,740	(5,841)	269,071
Balance (in shares) at Dec. 31, 2018		14,210
Balance at Dec. 31, 2018		$ 142	50,763	218,233	(5,526)	263,612
Net income (loss)						23,142
Balance (in shares) at Sep. 30, 2019		14,269
Balance at Sep. 30, 2019		$ 143	46,482	241,375	(6,318)	281,682
Balance (in shares) at Mar. 31, 2019		14,214
Balance at Mar. 31, 2019		$ 142	52,030	222,740	(5,841)	269,071
Forfeiture of restricted stock awards (in shares)		(7)
Stock-based compensation expense		$ 0	1,443	0	0	1,443
Repurchase of common stock (in shares)		(452)
Repurchase of common stock		$ (5)	(29,995)	0	0	(30,000)
Net income (loss)		0	0	9,435	0	9,435
Other comprehensive loss		$ 0	0	0	145	145
Issuance of common stock for equity awards (in shares)		30
Issuance of common stock for equity awards		$ 1	851	0	0	852
Stock-based compensation expense		$ 0	1,443	0	0	1,443
Balance (in shares) at Jun. 30, 2019		13,785
Balance at Jun. 30, 2019		$ 138	24,329	232,175	(5,696)	250,946
Forfeiture of restricted stock awards (in shares)		(2)
Stock-based compensation expense		$ 0	1,311	0	0	1,311
Retirement of common stock for minimum tax withholdings (in shares)		(2)
Retirement of common stock for minimum tax withholdings		$ 0	(120)	0	0	(120)
Net income (loss)		0	0	9,200	0	9,200
Other comprehensive loss		$ 0	0	0	(622)	(622)
Issuance of common stock for equity awards (in shares)		488
Issuance of common stock for equity awards		$ 5	20,962	0	0	20,967
Stock-based compensation expense		$ 0	1,311	0	0	1,311
Balance (in shares) at Sep. 30, 2019		14,269
Balance at Sep. 30, 2019		$ 143	46,482	241,375	(6,318)	281,682
Balance (in shares) at Dec. 31, 2019		14,308
Balance at Dec. 31, 2019		$ 143	48,707	245,426	(5,898)	288,378
Vesting of restricted stock units (in shares)	42
Forfeiture of restricted stock awards (in shares)		(9)
Stock-based compensation expense		$ 0	(207)	0	0	(207)
Retirement of common stock for minimum tax withholdings (in shares)		(4)
Retirement of common stock for minimum tax withholdings		$ 0	(141)	0	0	(141)
Repurchase of common stock (in shares)		(139)
Repurchase of common stock		$ (1)	1	0	0	0
Net income (loss)		0	0	5,793	0	5,793
Other comprehensive loss		0	0	0	(129)	(129)
Stock-based compensation expense		$ 0	(207)	0	0	(207)
Balance (in shares) at Mar. 31, 2020		14,198
Balance at Mar. 31, 2020		$ 142	48,360	251,219	(6,027)	293,694
Balance (in shares) at Dec. 31, 2019		14,308
Balance at Dec. 31, 2019		$ 143	48,707	245,426	(5,898)	288,378
Net income (loss)						(8,326)
Balance (in shares) at Sep. 30, 2020		14,208
Balance at Sep. 30, 2020		$ 142	52,505	237,100	(5,296)	284,451
Balance (in shares) at Mar. 31, 2020		14,198
Balance at Mar. 31, 2020		$ 142	48,360	251,219	(6,027)	293,694
Vesting of restricted stock units (in shares)		7
Stock-based compensation expense		$ 0	2,240	0	0	2,240
Retirement of common stock for minimum tax withholdings (in shares)		(3)
Retirement of common stock for minimum tax withholdings		$ 0	(59)	0	0	(59)
Net income (loss)		0	0	(7,708)	0	(7,708)
Other comprehensive loss		$ 0	0	0	209	209
Issuance of common stock for equity awards (in shares)		2
Issuance of common stock for equity awards		$ 0	68	0	0	68
Stock-based compensation expense		$ 0	2,240	0	0	2,240
Balance (in shares) at Jun. 30, 2020		14,204
Balance at Jun. 30, 2020		$ 142	50,609	243,511	(5,818)	288,444
Vesting of restricted stock units (in shares)		4
Stock-based compensation expense		$ 0	1,920	0	0	1,920
Retirement of common stock for minimum tax withholdings		0	(24)	0	0	(24)
Net income (loss)		0	0	(6,411)	0	(6,411)
Other comprehensive loss		0	0	0	522	522
Stock-based compensation expense		$ 0	1,920	0	0	1,920
Balance (in shares) at Sep. 30, 2020		14,208
Balance at Sep. 30, 2020		$ 142	$ 52,505	$ 237,100	$ (5,296)	$ 284,451

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Cash flows from operating activities:
Net income (loss)	$ (6,411)	$ 5,793	$ 9,200	$ 4,507	$ (8,326)	$ 23,142
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					9,963	4,459
Payment of interest expense on finance leases					(22)	0
Non-cash operating lease cost					1,136	880
Goodwill impairment	0		0		18,144	0	$ 0
Change in fair value of contingent consideration	4,150		0		(16,176)	0
Loss on disposal of fixed assets					287	927
Loss on impairment of intangible asset					1,025	303	(389)
Stock-based compensation expense					3,953	4,140
Deferred income taxes					(3,302)	941
Provision (recovery) for doubtful accounts					(482)	(450)
Provision for inventory					4,205	1,062
Amortization of acquisition-related inventory step-up					7,396	0
Accretion of amortized cost of investments					3	(1,075)
Changes in operating assets and liabilities:
Accounts receivable					7,811	(2,751)
Inventories					(8,840)	(6,600)
Prepaid expenses, other current and long-term assets					(989)	440
Accounts payable					(1,904)	(335)
Operating lease liabilities					(1,286)	(796)
Accrued expenses, other current and long-term liabilities					(2,340)	(681)
Income taxes					222	377
Net cash provided by operating activities					10,478	23,983
Cash flows from investing activities:
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired					(93,859)	0
Proceeds from maturities of investments					27,000	87,594
Purchases of investments					(20,035)	(86,368)
Purchases of property and equipment					(1,179)	(2,559)
Net cash used in investing activities					(88,073)	(1,333)
Cash flows from financing activities:
Payments made on finance leases					(155)	0
Repurchases of common stock					0	(30,000)
Repayments of long term debt					(25,351)	0
Proceeds from long term debt					50,000	0
Cash paid for tax withheld on vested restricted stock awards					(224)	(245)
Proceeds from exercises of equity awards					68	21,825
Net cash provided by (used in) financing activities					24,338	(8,420)
Exchange rate impact on cash					10	109
(Decrease)/Increase in cash and cash equivalents					(53,247)	14,339
Cash and cash equivalents at beginning of period		$ 157,463		$ 89,042	157,463	89,042	89,042
Cash and cash equivalents at end of period	104,216		103,381		104,216	103,381	$ 157,463
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019	$ 603		$ 488		1,739	1,482
Non-cash Investing Activities:
Purchases of property and equipment included in accounts payable and accrued expenses					44	132
Consideration for acquisitions included in accounts payable and accrued expenses					1,209	0
Acquisition-related contingent consideration					69,076	0
Accounting Standards Update 2016-02 [Member]
Supplemental disclosure of cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019					$ 0	$ 24,110

Note 1 - Nature of Business

Note 1 - Nature of Business	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of Business Anika Therapeutics, Inc. (“the Company”), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. In early 2020, There continue to be uncertainties regarding the pandemic of the novel coronavirus (“COVID- 19” 19 19 may may 19. The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	2. Basis of Presentation The accompanying unaudited consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2019 The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10 December 31, 2019. three nine September 30, 2020 not December 31, 2020. Segment Information Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company's chief operating decision maker is its President and Chief Executive Officer. Based on the criteria established by Accounting Standards Codification (“ASC”) 280, Segment Reportin one Recent Accounting Adoptions In August 2018, No. 2018 15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350 40 No. 2015 05, Customers Accounting for Fees in a Cloud Computing Agreement 2018 15 350 40 2018 15 December 15, 2019. 2018 15 January 1, 2020. not In June 2016, No. 2016 13, Financial Instruments - Credit Losses 2016 13 December 15, 2019 2016 13 January 1, 2020. not not

Note 3 - Business Combinations

Note 3 - Business Combinations	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. Business Combinations Parcus Medical, LLC On January 24, 2020, January 4, 2020 ( The acquisition of Parcus Medical has been accounted for as a business combination under ASC 805. 805, no one January 24, 2020 Consideration Transferred Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, which consists of: Cash consideration $ 32,794 Deferred consideration 1,642 Estimated fair value of contingent consideration 40,700 Estimated total purchase consideration $ 75,136 Contingent consideration represents additional payments that the Company may 2020 2022. one September 30, 2020. Acquisition-related costs are not three March 31, 2020. March 31, 2020 Fair Value of Net Assets Acquired The preliminary estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not may one The preliminary allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on preliminary estimates of fair value as of January 24, 2020, Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 196 Accounts receivable 2,029 Inventories 10,968 Prepaid expenses and other current assets 364 Property and equipment, net 1,099 Right-of-use assets 944 Intangible assets 44,000 Accounts payable, accrued expenses and other current liabilities (2,763 ) Other long-term liabilities (594 ) Lease liabilities (735 ) Net assets acquired 55,508 Goodwill 19,628 Estimated total purchase consideration $ 75,136 During the three September 30, 2020, January 24, 2020 three nine September 30, 2020 not The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not January 24, 2020 Intangible assets acquired consist of: Developed technology $ 41,100 Trade name 1,800 Customer relationships 1,100 Total intangible assets $ 44,000 The preliminary fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The preliminary fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The preliminary fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset. The final fair value determination of the identified intangible assets may Revenue and Net Loss The Company recorded revenue from Parcus Medical of $3.3 million and a net loss of $1.6 million in the three September 30, 2020. January 24 September 30, 2020. Arthrosurface, Inc. On February 3, 2020, January 4, 2020 ( The acquisition of Arthrosurface has been accounted for as a business combination under ASC 805. 805, no one February 3, 2020 Consideration Transferred Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, which consists of: Cash consideration $ 61,909 Estimated fair value of contingent consideration 28,376 Estimated total purchase consideration $ 90,285 The Company may 2020 2021. 2020 2021 Acquisition-related costs are not three March 31, 2020. March 31, 2020 Fair Value of Net Assets Acquired The preliminary estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not may one The preliminary allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on preliminary estimates of fair value as of February 3, 2020, Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 1,072 Accounts receivable 5,368 Inventories 15,652 Prepaid expenses and other current assets 535 Property, plant and equipment 3,394 Other long-term assets 7,548 Intangible assets 48,900 Accounts payable, accrued expenses and other liabilities (3,929 ) Deferred tax liabilities (11,147 ) Net assets acquired 67,393 Goodwill 22,892 Estimated total purchase consideration $ 90,285 The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not not Intangible assets acquired consist of: Developed technology $ 37,000 Trade name 3,400 Customer relationships 7,900 IPR&D 600 Total intangible assets $ 48,900 The preliminary fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The preliminary fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The preliminary fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset. The final fair value determination of the identified intangible assets may Revenue and Net Loss The Company recorded revenue from Arthrosurface of $7.2 million and a net loss of $1.6 million in the three September 30, 2020. February 3 September 30, 2020. Pro forma Information The Parcus Medical and Arthrosurface acquisitions were both completed in the first 2020. 11, The unaudited pro forma information for the three nine September 30, 2020 2019 January 1, 2019 These pro forma adjustments include: (i) a net increase in amortization expense to record amortization expense for the aforementioned acquired identifiable intangible assets, (ii) an adjustment to cost of product revenue based on the preliminary fair value inventory adjustment and the anticipated inventory turnover, (iii) a net decrease in interest expense as a result of eliminating interest expense and interest income related to borrowings that were settled in accordance with the respective Parcus Merger Agreement and Arthrosurface Merger Agreement, (iv) an adjustment to record the acquisition-related transaction costs in the period required, and (v) the tax effect of the pro forma adjustments using the anticipated effective tax rate. The effective tax rate of the combined company could be materially different from the rate presented in this unaudited pro forma combined financial information. As a result of the transaction, the combined company may not The following table presents unaudited supplemental pro forma information: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Total revenue $ 31,694 $ 39,912 $ 101,722 $ 115,045 Net income (loss) (6,411 ) 4,909 (7,328 ) 7,296

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. Fair Value Measurements The Company held U.S. treasury bills of $15.0 million and certificates of deposit of $5.5 million at September 30, 2020. December 31, 2019. September 30, 2020 December 31, 2019, The Company’s investments are all classified within Levels 1 2 1 2 third not 3 The fair value hierarchy of the Company's cash equivalents, investments and liabilities at fair value was as follows: Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs September 30, 2020 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Money Market Funds $ 56,431 $ 56,431 $ - $ - $ 56,431 Investments: Bank Certificates of Deposit $ 5,503 $ - $ 5,503 $ - $ 5,516 U.S. Treasury Bills 15,039 15,039 - - 15,130 Total Investments $ 20,542 $ 15,039 $ 5,503 $ - $ 20,646 Other current and long-term liabilities: Contingent Consideration - Short Term $ 11,855 $ - $ - $ 11,855 $ - Contingent Consideration - Long Term 41,045 - - 41,045 - Total Other current and long-term liabilities $ 52,900 $ - $ - $ 52,900 $ - Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs December 31, 2019 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Money Market Funds $ 48,971 $ 48,971 $ - $ - $ 48,971 Investments: U.S. Treasury Bills $ 27,480 $ 27,480 $ - $ - $ 27,479 There were no nine September 30, 2020 2019. Contingent Consideration The following table provides a rollforward of the contingent consideration related to business acquisitions discussed in Note 3. Nine Months Ended September 30, 2020 Balance, beginning January 1, 2020 $ - Additions 69,076 Payments - Change in fair value (16,176 ) Balance, ending September 30, 2020 $ 52,900 Under the Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, there are earn-out milestones totaling $100 million payable from 2020 2022. 2020 2022, 2020 2021. September 30, 2020. 19 The fair value of contingent consideration is assessed on a quarterly basis. The fair value of contingent consideration increased by $4.2 million for the three September 30, 2020 third nine September 30, 2020 19 October 15, 2020,

Note 5 - Inventories

Note 5 - Inventories	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consist of the following: September 30, December 31, 2020 2019 Raw materials $ 12,973 $ 12,058 Work-in-process 12,372 8,330 Finished goods 35,259 8,777 Total $ 60,604 $ 29,165 Inventories $ 47,882 $ 21,995 Other long-term assets 12,722 7,170 The increase in inventories for the nine September 30, 2020 January February 2020, 3. The Company recorded an inventory reserve of $1.9 million during the three June 30, 2020 not not

Note 6 - Intangible Assets

Note 6 - Intangible Assets	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets Intangible assets as of September 30, 2020 December 31, 2019 Nine Months Ended September 30, 2020 Gross Value Less: Accumulated Currency Translation Adjustment Less: Current Period Impairment Charge Less: Accumulated Amortization Net Book Value Weighted Average Useful Life Developed technology $ 93,953 $ (2,766 ) $ (1,025 ) $ (12,919 ) $ 77,243 15 In-process research & development 5,006 (1,120 ) - - 3,886 Indefinite Customer relationships 9,000 - - (568 ) 8,432 10 Distributor relationships 4,700 (415 ) - (4,285 ) - 5 Patents 1,000 (167 ) - (602 ) 231 16 Tradenames 5,200 - - (701 ) 4,499 5 Total $ 118,859 $ (4,468 ) $ (1,025 ) $ (19,075 ) $ 94,291 13 Year Ended December 31, 2019 Gross Value Less: Accumulated Currency Translation Adjustment Less: Current Period Impairment Charge Less: Accumulated Amortization Net Book Value Weighted Average Useful Life Developed technology $ 17,100 $ (2,934 ) $ (389 ) $ (9,657 ) $ 4,120 15 In-process research & development 4,406 (1,234 ) - - 3,172 Indefinite Distributor relationships 4,700 (415 ) - (4,285 ) - 5 Patents 1,000 (176 ) - (531 ) 293 16 Elevess Tradename 1,000 - - (1,000 ) - 9 Total $ 28,206 $ (4,759 ) $ (389 ) $ (15,473 ) $ 7,585 11 The aggregate amortization expense related to intangible assets was $1.9 million and $0.3 million for the three September 30, 2020 2019, nine September 30, 2020 2019, In the first 2020, 3, six June 30, 2020, not For the quarter ended September 30, 2020, not

Note 7 - Goodwill

Note 7 - Goodwill	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Goodwill Disclosure [Text Block]	7. Goodwill The Company assesses goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may may first not may not not not no As of December 31, 2019, 2019 Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Balance, beginning $ 7,694 $ 7,851 Effect of foreign currency adjustments 349 (157 ) Acquisitions 42,520 - Impairment (18,144 ) - Balance, ending $ 32,419 $ 7,694 The increase in goodwill for the nine September 30, 2020 January February 2020 3. one The widespread economic volatility resulting from the COVID- 19 first 2020, not not not March 31, 2020. September 30, 2020, no may not U.S. government policy responses to the COVID- 19 first 2020, March 31, 2020. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, the achievement of certain cost synergies, terminal growth rates and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of March 31, 2020. The results of the interim impairment test indicated that the estimated fair value of the Parcus and Arthrosurface reporting unit was less than its carrying value. This was primarily due to decreases in near term revenue and related cash flows as a result of the temporary suspension of domestic elective procedures which directly impact the Parcus and Arthrosurface reporting unit. Consequently, a non-cash goodwill impairment charge was recorded as reflected in the table above as of March 31, 2020. September 30, 2020, no March 31, 2020 may not not

Note 8 - Leases

Note 8 - Leases	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Lessee, Operating Leases and Finance Leases [Text Block]	8. Leases The components of lease expense and other information are as follows: For the Three Months Ended For the Nine Months Ended September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019 Amortization of right-of-use assets $ 50 $ - $ 136 $ - Interest on finance lease liabilities 7 - 22 - Finance lease expense $ 57 $ - $ 158 $ - Operating lease expense 590 525 1,759 1,568 Short-term lease expense - - - 6 Variable lease expense 67 43 204 155 Total lease expense $ 714 $ 568 $ 2,121 $ 1,729 For the Three Months Ended For the Nine Months Ended September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019 Weighted Average Remaining Lease Term (in years) Operating leases 15.9 17.1 15.9 17.1 Financing leases 3.3 - 3.3 - Weighted Average Discount Rate Operating leases 4.1 % 4.1 % 4.1 % 4.1 % Financing leases 5.0 % - 5.0 % - Other information Operating cash flows from operating leases $ 603 $ 488 $ 1,739 $ 1,482 Operating cash flows from financing leases $ 59 $ - $ 110 $ - Future commitments due under these lease agreements as of September 30, 2020 Years ended December 31, Operating Leases Financing Leases Total 2020 (Remaining 3 months) $ 598 $ 59 $ 657 2021 2,304 170 2,474 2022 2,240 166 2,406 2023 2,123 160 2,283 2024 2,059 44 2,103 2025 1,924 - 1,924 Thereafter 19,450 - 19,450 Present value adjustment (8,103 ) (44 ) (8,147 ) Present value of lease payments 22,595 555 23,150 Less current portion included in accrued expenses and other current liabilities (1,463 ) (164 ) (1,627 ) Total lease liabilities $ 21,132 $ 391 $ 21,523

Note 9 - Accrued Expenses

Note 9 - Accrued Expenses	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	9. Accrued Expenses Accrued expenses consist of the following: September 30, December 31, Compensation and related expenses $ 6,559 $ 5,830 Professional fees 2,358 3,850 Operating lease liability - current 1,463 1,141 Clinical trial costs 910 788 Current portion of acquisition-related contingent consideration (Note 4) 11,855 - Finance lease liability - current 163 - Other 1,031 836 Total $ 24,339 $ 12,445

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may not third September 30, 2020 December 31, 2019 no The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not

Note 11 - Revenue

Note 11 - Revenue	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	11. Revenue The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and may September 30, 2020, The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (“Mitek”) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent 48% and 52% of total Company revenues for the three nine September 30, 2020, three nine September 30, 2019, may Revenue Recognition Associated with Acquired Businesses: Pursuant to ASC 606, Arthrosurface and Parcus Medical products are sold through two In direct channel accounts, inventory is generally consigned to sales agents so that products are available when needed for surgical procedures. No With sales to stocking distributors revenue is generally recognized when control of Arthrosurface and Parcus Medical product passes to the customer, which is typically upon shipment of the product. It is our accounting policy to account for shipping and handling activities as a fulfillment cost rather than as an additional promised service. The payment terms with respect to sales through both channels are consistent with prevailing practice in the respective markets in which the Company does business. Payment terms align with the one Product and Total Revenue Historically, the Company categorized its product offerings into four first 2020, three January 24, 2020 February 3, 2020 Product revenue by product family was as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Joint Pain Management $ 18,439 $ 27,581 $ 66,168 $ 77,063 Orthopedic Joint Preservation and Restoration 11,715 544 26,233 1,510 Other 1,540 1,490 5,368 6,172 $ 31,694 $ 29,615 $ 97,769 $ 84,745 Total revenue by geographic location was as follows: Three Months Ended September 30, 2020 2019 Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 26,409 84 % $ 23,512 79 % Europe 2,954 9 % 3,943 13 % Other 2,331 7 % 2,242 8 % Total $ 31,694 100 % $ 29,697 100 % Nine Months Ended September 30, 2020 2019 Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 77,848 80 % $ 66,538 78 % Europe 11,140 11 % 11,396 14 % Other 8,781 9 % 6,904 8 % Total $ 97,769 100 % $ 84,838 100 %

Note 12 - Equity Incentive Plan

Note 12 - Equity Incentive Plan	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Equity Incentive Plan The Company estimates the fair value of stock options and stock appreciation rights (“SARs”) using the Black-Scholes valuation model, and estimates the fair value of the total shareholder return options (“TSRs”) using a Monte-Carlo simulation model as of the grant date. Fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) is measured by the grant-date price of the Company’s shares. Fair value of performance restricted stock units (“PSUs”) is measured by the grant-date price of the Company’s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost of PSUs is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are not no The fair value of each stock option award during the nine September 30, 2020 2019 Nine months ended 2020 2019 Risk free interest rate 0.21% - 1.59% 1.41% - 2.54% Expected volatility 46.48% - 52.99% 44.27% - 46.21% Expected life (years) 4.0 - 6.3 3.5 Expected dividend yield 0.00% 0.00% The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of product revenue $ 202 $ 114 $ 564 $ 288 Research & development 206 50 558 318 Selling, general & administrative 1,512 1,147 2,832 3,534 Total stock-based compensation expense $ 1,920 $ 1,311 $ 3,954 $ 4,140 The Company’s former President and Chief Executive Officer, Joseph Darling, passed unexpectedly in January 2020. 2017 “2017 one three March 31, 2020 The following table sets forth share information for stock-based compensation awards granted and exercised during the three nine September 30, 2020 2019: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Grants: Stock options 85,345 87,250 402,558 218,867 RSUs 34,697 9,000 218,804 185,507 PSUs 16,077 9,000 162,297 123,500 TSRs - - 104,638 - Exercises: Stock options - 488,586 2,146 511,486 Forfeitures: Stock options 32,629 42,566 86,732 81,638 RSAs - 1,975 8,574 12,533 RSUs 17,937 7,500 90,103 19,100 PSUs 19,000 4,500 90,000 13,500 Expirations: Stock options 3,083 25,697 3,646 44,829 During the three nine September 30, 2020, three 2020 2022 2020 2022 three nine September 30, 2020. During the second 2020, may three nine September 30, 2020,

Note 13 - Earnings Per Share ("

Note 13 - Earnings Per Share ("EPS")	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	13. Earnings Per Share (“EPS”) Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not The following table provides share information used in the calculation of the Company's basic and diluted earnings (loss) per share: Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Shares used in the calculation of basic earnings per share 14,205 14,070 14,202 14,065 Effect of dilutive securities: Share-based payment awards - 317 - 201 Diluted shares used in the calculation of earnings per share 14,205 14,387 14,202 14,266 For the three nine September 30, 2020, three September 30, 2020 2019 not nine September 30, 2020 2019 not

Note 14 - Accelerated Share Rep

Note 14 - Accelerated Share Repurchase	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Accelerated Share Repurchases Disclosure [Text Block]	14. Accelerated Share Repurchase In May 2019, May 7, 2019, May 2019 January 2020, January 14, 2020. September 30, 2020, no

Note 15 - Income Taxes

Note 15 - Income Taxes	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	15. Income Taxes In response to the COVID- 19 March 2020. not The benefit from income taxes was $1.7 million and $2.2 million for the three nine September 30, 2020, three nine September 30, 2019, three nine September 30, 2020, 2019, 3. The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In connection with the preparation of the financial statements, the Company assesses whether it was more likely than not September 30, 2020, not” not

Note 16 - Revolving Credit Agre

Note 16 - Revolving Credit Agreement	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	16. Revolving Credit Agreement On April 8, 2020, three nine September 30, 2020 three September 30, 2020, September 30, 2020, October 2022, may may The existing credit facility was entered into on October 24, 2017. five may one five December 31, 2019 2018, not first

Note 17 - Subsequent Events

Note 17 - Subsequent Events	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	17. Subsequent Events On October 15, 2020,

Note 3 - Business Combinations

Note 3 - Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	Cash consideration $ 32,794 Deferred consideration 1,642 Estimated fair value of contingent consideration 40,700 Estimated total purchase consideration $ 75,136 Cash consideration $ 61,909 Estimated fair value of contingent consideration 28,376 Estimated total purchase consideration $ 90,285
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 196 Accounts receivable 2,029 Inventories 10,968 Prepaid expenses and other current assets 364 Property and equipment, net 1,099 Right-of-use assets 944 Intangible assets 44,000 Accounts payable, accrued expenses and other current liabilities (2,763 ) Other long-term liabilities (594 ) Lease liabilities (735 ) Net assets acquired 55,508 Goodwill 19,628 Estimated total purchase consideration $ 75,136 Recognized identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 1,072 Accounts receivable 5,368 Inventories 15,652 Prepaid expenses and other current assets 535 Property, plant and equipment 3,394 Other long-term assets 7,548 Intangible assets 48,900 Accounts payable, accrued expenses and other liabilities (3,929 ) Deferred tax liabilities (11,147 ) Net assets acquired 67,393 Goodwill 22,892 Estimated total purchase consideration $ 90,285
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	Intangible assets acquired consist of: Developed technology $ 41,100 Trade name 1,800 Customer relationships 1,100 Total intangible assets $ 44,000 Intangible assets acquired consist of: Developed technology $ 37,000 Trade name 3,400 Customer relationships 7,900 IPR&D 600 Total intangible assets $ 48,900
Business Acquisition, Pro Forma Information [Table Text Block]	For the Three Months Ended September 30, For the Nine Months Ended September 30, 2020 2019 2020 2019 Total revenue $ 31,694 $ 39,912 $ 101,722 $ 115,045 Net income (loss) (6,411 ) 4,909 (7,328 ) 7,296

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs September 30, 2020 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Money Market Funds $ 56,431 $ 56,431 $ - $ - $ 56,431 Investments: Bank Certificates of Deposit $ 5,503 $ - $ 5,503 $ - $ 5,516 U.S. Treasury Bills 15,039 15,039 - - 15,130 Total Investments $ 20,542 $ 15,039 $ 5,503 $ - $ 20,646 Other current and long-term liabilities: Contingent Consideration - Short Term $ 11,855 $ - $ - $ 11,855 $ - Contingent Consideration - Long Term 41,045 - - 41,045 - Total Other current and long-term liabilities $ 52,900 $ - $ - $ 52,900 $ - Fair Value Measurements at Reporting Date Using Quoted Prices in Active Markets Significant Other Significant for Identical Assets Observable Inputs Unobservable Inputs December 31, 2019 (Level 1) (Level 2) (Level 3) Amortized Cost Cash equivalents: Money Market Funds $ 48,971 $ 48,971 $ - $ - $ 48,971 Investments: U.S. Treasury Bills $ 27,480 $ 27,480 $ - $ - $ 27,479
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Nine Months Ended September 30, 2020 Balance, beginning January 1, 2020 $ - Additions 69,076 Payments - Change in fair value (16,176 ) Balance, ending September 30, 2020 $ 52,900

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2020 2019 Raw materials $ 12,973 $ 12,058 Work-in-process 12,372 8,330 Finished goods 35,259 8,777 Total $ 60,604 $ 29,165 Inventories $ 47,882 $ 21,995 Other long-term assets 12,722 7,170

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]	Nine Months Ended September 30, 2020 Gross Value Less: Accumulated Currency Translation Adjustment Less: Current Period Impairment Charge Less: Accumulated Amortization Net Book Value Weighted Average Useful Life Developed technology $ 93,953 $ (2,766 ) $ (1,025 ) $ (12,919 ) $ 77,243 15 In-process research & development 5,006 (1,120 ) - - 3,886 Indefinite Customer relationships 9,000 - - (568 ) 8,432 10 Distributor relationships 4,700 (415 ) - (4,285 ) - 5 Patents 1,000 (167 ) - (602 ) 231 16 Tradenames 5,200 - - (701 ) 4,499 5 Total $ 118,859 $ (4,468 ) $ (1,025 ) $ (19,075 ) $ 94,291 13 Year Ended December 31, 2019 Gross Value Less: Accumulated Currency Translation Adjustment Less: Current Period Impairment Charge Less: Accumulated Amortization Net Book Value Weighted Average Useful Life Developed technology $ 17,100 $ (2,934 ) $ (389 ) $ (9,657 ) $ 4,120 15 In-process research & development 4,406 (1,234 ) - - 3,172 Indefinite Distributor relationships 4,700 (415 ) - (4,285 ) - 5 Patents 1,000 (176 ) - (531 ) 293 16 Elevess Tradename 1,000 - - (1,000 ) - 9 Total $ 28,206 $ (4,759 ) $ (389 ) $ (15,473 ) $ 7,585 11

Note 7 - Goodwill (Tables)

Note 7 - Goodwill (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Goodwill [Table Text Block]	Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Balance, beginning $ 7,694 $ 7,851 Effect of foreign currency adjustments 349 (157 ) Acquisitions 42,520 - Impairment (18,144 ) - Balance, ending $ 32,419 $ 7,694

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Lease, Cost [Table Text Block]	For the Three Months Ended For the Nine Months Ended September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019 Amortization of right-of-use assets $ 50 $ - $ 136 $ - Interest on finance lease liabilities 7 - 22 - Finance lease expense $ 57 $ - $ 158 $ - Operating lease expense 590 525 1,759 1,568 Short-term lease expense - - - 6 Variable lease expense 67 43 204 155 Total lease expense $ 714 $ 568 $ 2,121 $ 1,729 For the Three Months Ended For the Nine Months Ended September 30, 2020 September 30, 2019 September 30, 2020 September 30, 2019 Weighted Average Remaining Lease Term (in years) Operating leases 15.9 17.1 15.9 17.1 Financing leases 3.3 - 3.3 - Weighted Average Discount Rate Operating leases 4.1 % 4.1 % 4.1 % 4.1 % Financing leases 5.0 % - 5.0 % - Other information Operating cash flows from operating leases $ 603 $ 488 $ 1,739 $ 1,482 Operating cash flows from financing leases $ 59 $ - $ 110 $ -
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]	Years ended December 31, Operating Leases Financing Leases Total 2020 (Remaining 3 months) $ 598 $ 59 $ 657 2021 2,304 170 2,474 2022 2,240 166 2,406 2023 2,123 160 2,283 2024 2,059 44 2,103 2025 1,924 - 1,924 Thereafter 19,450 - 19,450 Present value adjustment (8,103 ) (44 ) (8,147 ) Present value of lease payments 22,595 555 23,150 Less current portion included in accrued expenses and other current liabilities (1,463 ) (164 ) (1,627 ) Total lease liabilities $ 21,132 $ 391 $ 21,523

Note 9 - Accrued Expenses (Tabl

Note 9 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, Compensation and related expenses $ 6,559 $ 5,830 Professional fees 2,358 3,850 Operating lease liability - current 1,463 1,141 Clinical trial costs 910 788 Current portion of acquisition-related contingent consideration (Note 4) 11,855 - Finance lease liability - current 163 - Other 1,031 836 Total $ 24,339 $ 12,445

Note 11 - Revenue (Tables)

Note 11 - Revenue (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Joint Pain Management $ 18,439 $ 27,581 $ 66,168 $ 77,063 Orthopedic Joint Preservation and Restoration 11,715 544 26,233 1,510 Other 1,540 1,490 5,368 6,172 $ 31,694 $ 29,615 $ 97,769 $ 84,745
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]	Three Months Ended September 30, 2020 2019 Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 26,409 84 % $ 23,512 79 % Europe 2,954 9 % 3,943 13 % Other 2,331 7 % 2,242 8 % Total $ 31,694 100 % $ 29,697 100 % Nine Months Ended September 30, 2020 2019 Total Percentage of Total Percentage of Revenue Revenue Revenue Revenue Geographic Location: United States $ 77,848 80 % $ 66,538 78 % Europe 11,140 11 % 11,396 14 % Other 8,781 9 % 6,904 8 % Total $ 97,769 100 % $ 84,838 100 %

Note 12 - Equity Incentive Pl_2

Note 12 - Equity Incentive Plan (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine months ended 2020 2019 Risk free interest rate 0.21% - 1.59% 1.41% - 2.54% Expected volatility 46.48% - 52.99% 44.27% - 46.21% Expected life (years) 4.0 - 6.3 3.5 Expected dividend yield 0.00% 0.00%
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of product revenue $ 202 $ 114 $ 564 $ 288 Research & development 206 50 558 318 Selling, general & administrative 1,512 1,147 2,832 3,534 Total stock-based compensation expense $ 1,920 $ 1,311 $ 3,954 $ 4,140
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Grants: Stock options 85,345 87,250 402,558 218,867 RSUs 34,697 9,000 218,804 185,507 PSUs 16,077 9,000 162,297 123,500 TSRs - - 104,638 - Exercises: Stock options - 488,586 2,146 511,486 Forfeitures: Stock options 32,629 42,566 86,732 81,638 RSAs - 1,975 8,574 12,533 RSUs 17,937 7,500 90,103 19,100 PSUs 19,000 4,500 90,000 13,500 Expirations: Stock options 3,083 25,697 3,646 44,829

Note 13 - Earnings Per Share _2

Note 13 - Earnings Per Share ("EPS") (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Shares used in the calculation of basic earnings per share 14,205 14,070 14,202 14,065 Effect of dilutive securities: Share-based payment awards - 317 - 201 Diluted shares used in the calculation of earnings per share 14,205 14,387 14,202 14,266

Note 3 - Business Combination_2

Note 3 - Business Combinations (Details Textual) - USD ($) $ in Thousands	Feb. 03, 2020	Jan. 24, 2020	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Asset, Useful Life (Year)							13 years	11 years
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)							15 years	15 years
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life (Year)							10 years
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life (Year)							5 years
Parcus Medical [Member]
Business Combination, Consideration Transferred, Total		$ 75,136
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High		60,000
Business Combination, Acquisition Related Costs				$ 1,900
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory		10,968
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		44,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 3,300		$ 7,900
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			(1,600)		(4,500)
Parcus Medical [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 41,100
Finite-Lived Intangible Asset, Useful Life (Year)		15 years
Parcus Medical [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 1,100
Finite-Lived Intangible Asset, Useful Life (Year)		10 years
Parcus Medical [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 1,800
Finite-Lived Intangible Asset, Useful Life (Year)		5 years
Parcus Medical [Member] | Trunk Stock [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			1,900		$ 1,900	$ 1,900	$ 1,900
Arthrosurface [Member]
Business Combination, Consideration Transferred, Total	$ 90,285
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High	40,000
Business Combination, Acquisition Related Costs				$ 2,200
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	15,652
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	48,900
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			7,200			15,600
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual			$ (1,600)			$ 8,400
Arthrosurface [Member] | Developed Technology Rights [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 37,000
Finite-Lived Intangible Asset, Useful Life (Year)	15 years
Arthrosurface [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 7,900
Finite-Lived Intangible Asset, Useful Life (Year)	10 years
Arthrosurface [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 3,400
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Arthrosurface [Member] | In Process Research and Development [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 600

Note 3 - Business Combination_3

Note 3 - Business Combinations - Consideration Transferred (Details) - USD ($) $ in Thousands	Feb. 03, 2020	Jan. 24, 2020
Parcus Medical [Member]
Cash consideration		$ 32,794
Deferred consideration		1,642
Estimated fair value of contingent consideration		40,700
Estimated total purchase consideration		$ 75,136
Arthrosurface [Member]
Cash consideration	$ 61,909
Estimated fair value of contingent consideration	28,376
Estimated total purchase consideration	$ 90,285

Note 3 - Business Combination_4

Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Feb. 03, 2020	Jan. 24, 2020	Dec. 31, 2019	Dec. 31, 2018
Goodwill	$ 32,419			$ 7,694	$ 7,851
Parcus Medical [Member]
Cash and cash equivalents			$ 196
Accounts receivable			2,029
Inventories			10,968
Prepaid expenses and other current assets			364
Property and equipment, net			1,099
Right-of-use assets			944
Intangible assets			44,000
Accounts payable, accrued expenses and other current liabilities			(2,763)
Other long-term liabilities			(594)
Lease liabilities			(735)
Net assets acquired			55,508
Goodwill			19,628
Estimated total purchase consideration			$ 75,136
Arthrosurface [Member]
Cash and cash equivalents		$ 1,072
Accounts receivable		5,368
Inventories		15,652
Prepaid expenses and other current assets		535
Property and equipment, net		3,394
Intangible assets		48,900
Accounts payable, accrued expenses and other current liabilities		(3,929)
Net assets acquired		67,393
Goodwill		22,892
Estimated total purchase consideration		90,285
Other long-term assets		7,548
Deferred tax liabilities	$ (11,200)	$ (11,147)

Note 3 - Business Combination_5

Note 3 - Business Combinations - Intangible Assets Acquired (Details) - USD ($) $ in Millions	Feb. 03, 2020	Jan. 24, 2020
Parcus Medical [Member]
Intangible assets		$ 44
Arthrosurface [Member]
Intangible assets	$ 48.9
Developed Technology Rights [Member] | Parcus Medical [Member]
Intangible assets		41.1
Developed Technology Rights [Member] | Arthrosurface [Member]
Intangible assets	37
Trade Names [Member] | Parcus Medical [Member]
Intangible assets		1.8
Trade Names [Member] | Arthrosurface [Member]
Intangible assets	3.4
Customer Relationships [Member] | Parcus Medical [Member]
Intangible assets		$ 1.1
Customer Relationships [Member] | Arthrosurface [Member]
Intangible assets	7.9
In Process Research and Development [Member] | Arthrosurface [Member]
Intangible assets	$ 0.6

Note 3 - Business Combination_6

Note 3 - Business Combinations - Pro Forma Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Total revenue	$ 31,694	$ 39,912	$ 101,722	$ 115,045
Net income (loss)	$ (6,411)	$ 4,909	$ (7,328)	$ 7,296

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) $ in Thousands	Oct. 15, 2020USD ($)	Feb. 03, 2020USD ($)	Jan. 24, 2020USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2019USD ($)	Dec. 31, 2019USD ($)
Certificates of Deposit, at Carrying Value				$ 5,500		$ 5,500
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				4,150	$ 0	(16,176)	$ 0
Subsequent Event [Member]
Payment for Contingent Consideration Liability, Financing Activities	$ 5,000
COVID 19 [Member]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability				$ 4,200		(16,200)
Parcus Medical and Arthrosurface Acquisitions [Member]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High						$ 100,000
Parcus Medical and Arthrosurface Acquisitions [Member] | Measurement Input, Discount Rate [Member] | Regulatory Earn Out Milestone [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.020		0.020
Parcus Medical and Arthrosurface Acquisitions [Member] | Measurement Input, Discount Rate [Member] | Regulatory Earn Out Milestone [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.025		0.025
Arthrosurface [Member]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High		$ 40,000
Arthrosurface [Member] | Probability of Achievement [Member] | Regulatory Earn Out Milestone [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.60		0.60
Arthrosurface [Member] | Probability of Achievement [Member] | Regulatory Earn Out Milestone [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.90		0.90
Arthrosurface [Member] | Measurement Input, Weighted Average Cost of Capital [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.115		0.115
Arthrosurface [Member] | Measurement Input, Weighted Average Cost of Capital [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.130		0.130
Parcus Medical [Member]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High			$ 60,000
Parcus Medical [Member] | Measurement Input, Weighted Average Cost of Capital [Member] | Minimum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.145		0.145
Parcus Medical [Member] | Measurement Input, Weighted Average Cost of Capital [Member] | Maximum [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input				0.150		0.150
US Treasury Bill Securities [Member]
Debt Securities, Available-for-sale, Total				$ 15,000		$ 15,000		$ 27,500

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Contingent Consideration - Short Term	$ 11,855	$ 0
Contingent Consideration - Long Term	41,045	0
Estimate of Fair Value Measurement [Member]
Investments	20,542
Contingent Consideration - Short Term	11,855
Contingent Consideration - Long Term	41,045
Total Other current and long-term liabilities	52,900
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Investments	15,039
Contingent Consideration - Short Term	0
Contingent Consideration - Long Term	0
Total Other current and long-term liabilities	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Investments	5,503
Contingent Consideration - Short Term	0
Contingent Consideration - Long Term	0
Total Other current and long-term liabilities	0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Investments	0
Contingent Consideration - Short Term	11,855
Contingent Consideration - Long Term	41,045
Total Other current and long-term liabilities	52,900
Reported Value Measurement [Member]
Investments	20,646
Contingent Consideration - Short Term	0
Contingent Consideration - Long Term	0
Total Other current and long-term liabilities	0
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]
Cash equivalents	56,431	48,971
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	56,431	48,971
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	0	0
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents	0	0
Money Market Funds [Member] | Reported Value Measurement [Member]
Cash equivalents	56,431	48,971
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]
Cash equivalents	5,503
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Cash equivalents	0
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Cash equivalents	5,503
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Cash equivalents	0
Certificates of Deposit [Member] | Reported Value Measurement [Member]
Cash equivalents	5,516
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member]
Investments	15,039	27,480
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]
Investments	15,039	27,480
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Investments	0	0
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]
Investments	0	0
US Treasury Securities [Member] | Reported Value Measurement [Member]
Investments	$ 15,130	$ 27,479

Note 4 - Fair Value Measureme_5

Note 4 - Fair Value Measurements - Contingent Consideration (Details) - Contingent Consideration [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Balance, beginning January 1, 2020	$ 0
Additions	69,076
Payments	0
Change in fair value	(16,176)
Balance, ending September 30, 2020	$ 52,900

Note 5 - Inventories (Details T

Note 5 - Inventories (Details Textual) $ in Millions	Jun. 30, 2020USD ($)
Inventory Valuation Reserves, Ending Balance	$ 1.9

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Raw materials	$ 12,973	$ 12,058
Work-in-process	12,372	8,330
Finished goods	35,259	8,777
Total	60,604	29,165
Inventories	47,882	21,995
Other long-term assets	$ 12,722	$ 7,170

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Amortization of Intangible Assets, Total	$ 1,900		$ 300		$ 5,400	$ 800
Impairment of Intangible Assets, Finite-lived					$ 1,025	$ 303	$ (389)
Asset Impairment Charges, Total	$ 0
Parcus Medical and Arthrosurface [Member]
Finite-lived Intangible Assets Acquired		$ 92,900
Parcus Medical and Arthrosurface [Member] | Selling, General and Administrative Expenses [Member]
Impairment of Intangible Assets, Finite-lived				$ 1,000

Note 6 - Intangible Assets - Su

Note 6 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Gross value	$ 118,859		$ 28,206
Accumulated Currency Translation Adjustment	(4,468)		(4,759)
Current period impairment charge	(1,025)	$ (303)	389
Accumulated Amortization	(19,075)		(15,473)
Net book value	$ 94,291		$ 7,585
Useful life (Year)	13 years		11 years
Loss on impairment of intangible asset	$ 1,025	$ 303	$ (389)
In Process Research and Development [Member]
Gross value	5,006		4,406
Accumulated Currency Translation Adjustment	(1,120)		(1,234)
Current period impairment charge	0		0
Accumulated Amortization	0		0
Net book value	3,886		3,172
Loss on impairment of intangible asset	0		0
Developed Technology Rights [Member]
Gross value	93,953		17,100
Accumulated Currency Translation Adjustment	(2,766)		(2,934)
Current period impairment charge	(1,025)		389
Accumulated Amortization	(12,919)		(9,657)
Net book value	$ 77,243		$ 4,120
Useful life (Year)	15 years		15 years
Loss on impairment of intangible asset	$ 1,025		$ (389)
Customer Relationships [Member]
Gross value	9,000
Accumulated Currency Translation Adjustment	0
Current period impairment charge	0
Accumulated Amortization	(568)
Net book value	$ 8,432
Useful life (Year)	10 years
Loss on impairment of intangible asset	$ 0
Distribution Rights [Member]
Gross value	4,700		4,700
Accumulated Currency Translation Adjustment	(415)		(415)
Current period impairment charge	0		0
Accumulated Amortization	(4,285)		(4,285)
Net book value	$ 0		$ 0
Useful life (Year)	5 years		5 years
Loss on impairment of intangible asset	$ 0		$ 0
Patents [Member]
Gross value	1,000		1,000
Accumulated Currency Translation Adjustment	(167)		(176)
Current period impairment charge	0		0
Accumulated Amortization	(602)		(531)
Net book value	$ 231		$ 293
Useful life (Year)	16 years		16 years
Loss on impairment of intangible asset	$ 0		$ 0
Elevess Trade Name [Member]
Gross value			1,000
Accumulated Currency Translation Adjustment			0
Current period impairment charge			0
Accumulated Amortization			(1,000)
Net book value			$ 0
Useful life (Year)			9 years
Loss on impairment of intangible asset			$ 0
Trade Names [Member]
Gross value	5,200
Accumulated Currency Translation Adjustment	0
Current period impairment charge	0
Accumulated Amortization	(701)
Net book value	$ 4,499
Useful life (Year)	5 years
Loss on impairment of intangible asset	$ 0

Note 7 - Goodwill (Details Text

Note 7 - Goodwill (Details Textual)	9 Months Ended
	Sep. 30, 2020
Number of Reporting Units	2

Note 7 - Goodwill - Changes in

Note 7 - Goodwill - Changes in the Carrying Value of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Balance			$ 7,694	$ 7,851	$ 7,851
Effect of foreign currency adjustments			349		(157)
Acquisitions			42,520		0
Impairment	$ 0	$ 0	(18,144)	$ 0	0
Balance	$ 32,419		$ 32,419		$ 7,694

Note 8 - Leases - Lease Expense

Note 8 - Leases - Lease Expense and Other Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Amortization of right-of-use assets	$ 50	$ 0	$ 136	$ 0
Interest on finance lease liabilities	7	0	22	0
Finance lease expense	57	0	158	0
Operating lease expense	590	525	1,759	1,568
Short-term lease expense	0	0	0	6
Variable lease expense	67	43	204	155
Total lease expense	$ 714	$ 568	$ 2,121	$ 1,729
Operating leases (Year)	15 years 10 months 24 days	17 years 1 month 6 days	15 years 10 months 24 days	17 years 1 month 6 days
Financing leases (Year)	3 years 3 months 18 days		3 years 3 months 18 days
Operating leases	4.10%	4.10%	4.10%	4.10%
Financing leases	5.00%	0.00%	5.00%	0.00%
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019	$ 603	$ 488	$ 1,739	$ 1,482
Operating cash flows from financing leases	$ 59	$ 0	$ 110	$ 0

Note 8 - Leases - Future Minimu

Note 8 - Leases - Future Minimum Rental Payments for Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
2020 (Remaining 3 months), operating leases	$ 598
2020 (Remaining 6 months), financing leases	59
2020 (Remaining 3 months)	657
2021, operating leases	2,304
2021, financing leases	170
2021	2,474
2022, operating leases	2,240
2022, financing leases	166
2022	2,406
2023, operating leases	2,123
2023, financing leases	160
2023	2,283
2024, operating leases	2,059
2024, financing leases	44
2024	2,103
2025, operating leases	1,924
Thereafter, operating leases	19,450
Thereafter, financing leases	0
Thereafter	19,450
Present value adjustment, operating leases	(8,103)
Present value adjustment, financing leases	(44)
Present value adjustment	(8,147)
Less current portion included in Accrued expenses and other current liabilities, operating leases	(1,463)	$ (1,141)
Less current portion included in Accrued expenses and other current liabilities, financing leases	(163)	0
Total lease liabilities, operating leases	21,132	$ 21,367
Total lease liabilities, financing leases	391
Total lease liabilities	21,523
Liabilities [Member]
Present value of lease payments, operating leases	22,595
Present value of lease payments, financing leases	555
Present value of lease payments	23,150
Accrued Expenses and Other Current Liabilities [Member]
Less current portion included in Accrued expenses and other current liabilities, operating leases	(1,463)
Less current portion included in Accrued expenses and other current liabilities, financing leases	(164)
Less current portion included in accrued expenses and other current liabilities	$ (1,627)

Note 9 - Accrued Expenses - Sum

Note 9 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Compensation and related expenses	$ 6,559	$ 5,830
Professional fees	2,358	3,850
Operating lease liability - current	1,463	1,141
Clinical trial costs	910	788
Current portion of acquisition-related contingent consideration (Note 4)	11,855	0
Finance lease liability - current	163	0
Other	1,031	836
Total	$ 24,339	$ 12,445

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Standard and Extended Product Warranty Accrual, Ending Balance	$ 0	$ 0

Note 11 - Revenue (Details Text

Note 11 - Revenue (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Mitek [Member]
Revenues From Agreements as Percent of Total Revenue	48.00%	71.00%	52.00%	70.00%

Note 11 - Revenue - Product Rev

Note 11 - Revenue - Product Revenue by Product Group (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 31,694	$ 29,697	$ 97,769	$ 84,838
Joint Pain Management Therapies [Member]
Revenue	18,439	27,581	66,168	77,063
Orthopedic Joint Preservation and Restoration Care [Member]
Revenue	11,715	544	26,233	1,510
Manufactured Product, Other [Member]
Revenue	1,540	1,490	5,368	6,172
Product [Member]
Revenue	$ 31,694	$ 29,615	$ 97,769	$ 84,745

Note 11 - Revenue - Total Reven

Note 11 - Revenue - Total Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue	$ 31,694	$ 29,697	$ 97,769	$ 84,838
Percentage of Revenue	100.00%	100.00%	100.00%	100.00%
UNITED STATES
Revenue	$ 26,409	$ 23,512	$ 77,848	$ 66,538
Percentage of Revenue	84.00%	79.00%	80.00%	78.00%
Europe [Member]
Revenue	$ 2,954	$ 3,943	$ 11,140	$ 11,396
Percentage of Revenue	9.00%	13.00%	11.00%	14.00%
Other Location [Member]
Revenue	$ 2,331	$ 2,242	$ 8,781	$ 6,904
Percentage of Revenue	7.00%	8.00%	9.00%	8.00%

Note 12 - Equity Incentive Pl_3

Note 12 - Equity Incentive Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation, One-time Benefit for Unexpected Death of Former President			$ 1,800
Share-based Payment Arrangement, Expense	$ 1,920			$ 1,311	$ 3,954	$ 4,140
Stock Options, PSUs and RSUs to Employees and RSUs to Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)					3 years
Performance Shares [Member]
Performance Conditions, Business Target, Percentage of Performance Conditions Based on Achievement in Current Fiscal Year					40.00%
Performance Conditions, Financial Target, Percentage of Performance Conditions Based on Company’s Operating Results in next Fiscal Year					60.00%
Share-based Payment Arrangement, Expense	200
Performance Shares [Member] | Maximum [Member]
Share-based Payment Arrangement, Expense					$ 100
Total Shareholder Return ("TSRs") Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		2 years 8 months 12 days
Share-based Payment Arrangement, Expense	$ 200				$ 400
Total Shareholder Return ("TSRs") Options [Member] | President and Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total (in shares)		104,638
Total Shareholder Return ("TSRs") Options [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number		150.00%
Total Shareholder Return ("TSRs") Options [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number		0.00%

Note 12 - Equity Incentive Pl_4

Note 12 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Expected life (years) (Year)		3 years 6 months
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Risk free interest rate	0.21%	1.41%
Expected volatility	46.48%	44.27%
Expected life (years) (Year)	4 years
Maximum [Member]
Risk free interest rate	1.59%	2.54%
Expected volatility	52.99%	46.21%
Expected life (years) (Year)	6 years 3 months 18 days

Note 12 - Equity Incentive Pl_5

Note 12 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Stock-based compensation expense	$ 1,920	$ 1,311	$ 3,954	$ 4,140
Cost of Sales [Member]
Stock-based compensation expense	202	114	564	288
Research and Development Expense [Member]
Stock-based compensation expense	206	50	558	318
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 1,512	$ 1,147	$ 2,832	$ 3,534

Note 12 - Equity Incentive Pl_6

Note 12 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Option [Member]
Grants (in shares)	85,345	87,250	402,558	218,867
Exercises (in shares)	0	488,586	2,146	511,486
Forfeitures (in shares)	32,629	42,566	86,732	81,638
Expirations (in shares)	3,083	25,697	3,646	44,829
Restricted Stock Units (RSUs) [Member]
Grants (in shares)	34,697	9,000	218,804	185,507
Forfeitures (in shares)	17,937	7,500	90,103	19,100
Performance Restricted Stock Units [Member]
Grants (in shares)	16,077	9,000	162,297	123,500
Forfeitures (in shares)	19,000	4,500	90,000	13,500
Total Shareholder Return ("TSRs") Options [Member]
Grants (in shares)	0	0	104,638	0
Restricted Stock [Member]
Forfeitures (in shares)	0	1,975	8,574	12,533

Note 13 - Earnings Per Share _3

Note 13 - Earnings Per Share ("EPS") (Details Textual) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1	0.4	0.8	0.7

Note 13 - Earnings Per Share _4

Note 13 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Basic weighted average common shares outstanding (in shares)	14,205	14,070	14,202	14,065
Share-based payment awards (in shares)	0	317	0	201
Diluted shares used in the calculation of earnings per share (in shares)	14,205	14,387	14,202	14,266

Note 14 - Accelerated Share R_2

Note 14 - Accelerated Share Repurchase (Details Textual) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Jan. 14, 2020	May 07, 2019	May 02, 2019
Stock Repurchase Program, Authorized Amount			$ 50
Accelerated Stock Repurchase [Member]
Stock Repurchase Program, Authorized Amount		$ 30	30
Accelerated Stock Repurchase [Member] | Morgan Stanley & Co., LLC [Member]
Stock Repurchased and Retired During Period, Shares (in shares)	0.6
Accelerated Share Repurchases, Final Price Paid Per Share (in dollars per share)	$ 50.78
Repurchase from Open Market [Member]
Stock Repurchase Program, Authorized Amount			$ 20

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Feb. 03, 2020
Income Tax Expense (Benefit), Total	$ (1,744)	$ 3,331	$ (2,161)	$ 7,817
Effective Income Tax Rate Reconciliation, Percent, Total	21.40%	26.60%	20.60%	25.30%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount	$ 1,900		$ 1,900
Effective Income Tax Rate Reconciliation,Change in Fair Value of Business Acquisition Contingent Consideration Liabilities, Amount	1,500		1,500
Deferred Tax Assets, Valuation Allowance, Total	500		500
Arthrosurface [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	$ 11,200		$ 11,200		$ 11,147

Note 16 - Revolving Credit Ag_2

Note 16 - Revolving Credit Agreement (Details Textual) - Revolving Credit Facility [Member] - USD ($) $ in Thousands	Apr. 08, 2020	Oct. 24, 2017	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Proceeds from Long-term Lines of Credit	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	2.08%
Interest Expense, Debt, Total			$ 300	$ 500
Repayments of Lines of Credit			25,000
Long-term Line of Credit, Total			$ 25,000	$ 25,000	$ 0	$ 0
Debt Instrument, Term (Year)		5 years
Line of Credit Facility, Current Borrowing Capacity		$ 50,000
Line of Credit Facility, Additional Borrowing Capacity		50,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 100,000
Line of Credit Facility, Commitment Fee Percentage		0.25%
Minimum [Member]
Debt Instrument, Basis Spread on Variable Rate		0.25%
Maximum [Member]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate		0.50%
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		1.00%

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) $ in Millions	Oct. 15, 2020USD ($)
Subsequent Event [Member]
Payment for Contingent Consideration Liability, Financing Activities	$ 5